

Press Release

¹⁸F-Flutrahexin is on the way, built on Nobel Prize awarded Click Chemistry technology!

Radeberg/Germany & Copenhagen/Denmark, 10th October, 2022

We are thrilled to announce that TetraKit Technologies and TRIMT have begun joint efforts towards developing a fluorine-18 labelled analogue of ⁶⁸Ga-Trivehexin for advanced diagnostics of various carcinomas (for example, pancreatic cancer, head-and-neck cancer, lung adenocarcinoma, ovarian carcinoma) and fibrotic diseases (lung, liver). Our collaborative development project represents a prime example for the high scientific value and outstanding practical applicability of the cutting-edge science that has been awarded with the Nobel Prize in Chemistry in 2022.

TetraKit Technologies develops a novel platform for multipurpose radiolabelling of biomolecules, especially with medical radionuclides. TetraKit's technological approach relies heavily on Nobel Prize Laureate Carolyn Bertozzi's bioorthogonal Click Chemistry. The patented TetraKit technology offers a very versatile and facile way to equip biomolecules with the nuclide ¹⁸F (fluorine-18) for detection with highly sensitive and spatially precise 3D imaging systems for patients, so-called positron emission tomography (PET) scanners.

TRIMT is working on its proprietary $\alpha\beta6$ -integrin ligand platform for targeting of predominantly oncological and other life-threatening diseases. The molecular assembly of TRIMT's lead compound Ga-68-Trivehexin, a PET radiopharmaceutical for non-invasive visualization of, e.g., pancreatic cancer, exploits a copper-catalyzed Click Chemistry method that has been independently published by Nobel Prize Laureates Barry K. Sharpless and Morten Meldal in 2002. TRIMT's ongoing research on advanced cancer therapeutics continues to rely on this Nobel awarded chemical methodology.

Both companies have joined forces in order to develop, qualify and validate a fluorine-18 labeled multipurpose cancer diagnostic agent called ¹⁸F-Flutrahexin, with an option to proceed towards therapeutic nuclides, such as the alpha emitter astatine-211 (²¹¹At) and others. The combination of both companies' technologies allows for broadening the scope of application of $\alpha\beta6$ -integrin targeting beyond the short-lived PET nuclide gallium-68, as well as the application of the TetraKit radiolabeling platform to boost the latest emerging molecular addressing system in nuclear and precision medicine.

"We were just thrilled to hear that the key chemical tools fueling our joint development plans now belong to the canon of Nobel Prize awarded scientific achievements", said the CSO of TetraKit, Prof. Matthias Herth from Copenhagen University. "Using this formidable technology, we are sure to be able to elaborate excellent diagnostic tools and advanced therapeutics to improve the clinical care for cancer patients", added the CEO of TRIMT GmbH, Dr. Jakub Šimeček.

Notes to Editors

About TETRAKIT

TetraKit Technologies develops the TetraKit platform, a novel technology for practical and kit-like theranostic radiolabeling of any biomolecule, especially focusing on astatine-211 and fluorine-18 for alpha therapy and PET imaging. The company was founded in 2021 in Copenhagen, Denmark.

About TRIMT

TRIMT GmbH is a clinical stage company, developing novel radiopharmaceuticals for diagnosis and treatment of life-threatening diseases. The company was founded in early 2021 in Radeberg near Dresden (Germany). TRIMT



holds a worldwide exclusive licence for various new radioligands based on technologies from the Technical University of Munich.

Contacts

Dr. Jakub Simecek (CEO)
TRIMT GmbH
Carl-Eschebach-Str. 7
01454 Radeberg, Germany
E: js@trimt.de
www.trimt.de

Dr. Andreas I. Jensen (CEO)
TetraKit Technologies ApS
Ole Maaløes Vej 3
2200 Copenhagen, Denmark
E: andreas.jensen@tetrakit.com
www.tetrakit.com